ReNerve eyes best session on record after US nerve repair tech approval

Renerve

13/11/2025 02:30

** Shares of Australia's ReNerve RNV.AX jump as much as 109.5% to A$0.22, marking their best session on record

** Stock hits its highest since March 28

** Medical device maker's nerve repair technology - NervAlign Nerve Cuff - gains approval for use across the US Department of Defense and Veterans Affairs healthcare systems

** Co adds that it has received both an initial purchase order and a subsequent repeat order from federal medical facilities

** Session lifts RNV to the green, shares up 2.9% YTD

(Reporting by Shruti Agarwal in Bengaluru)

((Shruti.Agarwal@thomsonreuters.com))